Targeting EZH2 and PRC2 dependence as novel anticancer therapy

Keyphrases

• Adverse Effects 9%
• B Cell Lymphomagenesis 9%
• B-cell Lymphoma 9%
• Biological Context 9%
• Cancer Genetics 9%
• Catalytic Activity 9%
• Catalytic Subunit 9%
• Cell Differentiation 9%
• Cell Identity 9%
• Chromatin Modification 9%
• Dynamic Regulation 9%
• Enhancer of Zeste Homolog 2 (EZH2) 100%
• Enzymatic Complex 9%
• Epigenetic Features 9%
• Epigenetic Machinery 9%
• Epigenetic Regulators 9%
• EZH1 9%
• Functional Crosstalk 18%
• Gain-of-function mutation 9%
• Gene Expression 9%
• Gene Regulation 9%
• Genetic Background 9%
• Genetic Characteristics 9%
• Genetic Events 9%
• Hematological Cancer 9%
• Hematological Malignancies 9%
• Highly Potent 9%
• Histone H3 9%
• Human Cancer 9%
• Internal Control Genes 9%
• Lysine 9%
• Malignant Hematopoiesis 9%
• Malignant Transformation 9%
• Methylation 9%
• Methyltransferase 9%
• Molecular Determinants 9%
• Molecular Predictors 9%
• Normal Hematopoiesis 9%
• Novel Anticancer Strategy 9%
• Novel Anticancer Therapies 100%
• Overexpression 9%
• Polycomb Repressive Complex 2 (PRC2) 100%
• Potentially Toxic 9%
• Precise Treatment 9%
• Promising Therapeutics 9%
• Recent Advances 9%
• Recurrent mutation 9%
• Small Molecule Inhibitors 9%
• SNF5 9%
• Somatic mutation 18%
• Therapeutic Interventions 9%
• Tissue Type 9%
• Tumor Suppressive Role 9%

Biochemistry, Genetics and Molecular Biology

• Adverse Effect 9%
• Anticancer 100%
• B Cell 18%
• Cancer Genetics 9%
• Cell Differentiation 9%
• Cellular Differentiation 9%
• Chromatin 9%
• Enzymatic Activity 9%
• Enzyme Active Site 9%
• EZH1 9%
• EZH2 100%
• Gain of Function Mutation 9%
• Gene Expression Control 9%
• Genetic Background 9%
• Genetic Transcription 9%
• Genetics 18%
• Hematopoiesis 9%
• Histone H3 9%
• Lysine 9%
• Malignant Transformation 9%
• Methylation 9%
• Methyltransferase 9%
• Polycomb Repressive Complex 2 100%
• Small Molecule 9%
• Somatic Mutation 18%